Biomarin Pharmaceutical Inc Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: November 2, 2026 results vs estimates
Biomarin Pharmaceutical Inc Forecast
Biomarin Pharmaceutical Inc short-term momentum is negative (up over 1 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term SELL signal. The long-term trend is negative (2 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 27.5% a year, a typical one-standard-deviation range is 53.21–57.49 over a week, 50.96–59.74 over a month and 40.13–70.57 over a year. (Signals as of 1 Nov 2026.)
Biomarin Pharmaceutical Inc Price Chart
Biomarin Pharmaceutical Inc Factors
YoY −13.6%
YoY −1.2%
YoY +155.3%
YoY +24.6%
YoY −33.8%
YoY −103.6%
YoY +2.0%
YoY −495.4%
YoY −785.9%
YoY −49.4%
YoY −57.2%
YoY −98.0%
YoY +571.4%
YoY −77.8%
YoY −65.1%
Biomarin Pharmaceutical Inc fundamentals: income statement, balance sheet & cash flow
Biomarin Pharmaceutical Inc reported revenue of $3.22bn and net income of $348.9m in FY2025, the year ended 31 December 2025 — revenue up 12.9% and net income down 18.3% on the prior year. Free cash flow was $725.0m. These figures are as reported in the filings, not restated: 28 fiscal years and 111 quarters of history, back to December 1998. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 3,221.3 | 2,853.9 | 2,419.2 | 2,096.0 | 1,846.3 |
| Cost of revenue | 736.8 | 580.2 | 532.1 | 503.0 | 470.5 |
| Gross profit | 2,484.4 | 2,273.7 | 1,887.2 | 1,593.0 | 1,375.8 |
| Research & development | 921.9 | 747.2 | 746.8 | 649.6 | 628.8 |
| Selling, general & admin. | — | — | 954.6 | 782.4 | 829.3 |
| Operating income | 533.5 | 484.2 | 185.8 | 161.0 | -82.3 |
| EBITDA | 572.9 | 650.5 | 306.8 | 265.4 | 47.4 |
| Interest expense | 10.9 | 12.7 | 17.3 | 16.0 | 15.3 |
| Pre-tax income | 482.5 | 541.8 | 188.6 | 149.6 | -75.4 |
| Income tax | 133.6 | 114.9 | 20.9 | 8.0 | -11.3 |
| Net income | 348.9 | 426.9 | 167.6 | 141.6 | -64.1 |
Download Biomarin Pharmaceutical Inc fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.BMRN.NASDAQ&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Biomarin Pharmaceutical Inc
Explore MacroFinance macro & markets research and analysis.
Biomarin Pharmaceutical Inc Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Biomarin Pharmaceutical Inc; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Biomarin Pharmaceutical Inc’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Biomarin Pharmaceutical Inc (United States)
Biomarin Pharmaceutical Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is Biomarin Pharmaceutical Inc?
What is the latest Biomarin Pharmaceutical Inc price?
Is Biomarin Pharmaceutical Inc in an uptrend?
How volatile is Biomarin Pharmaceutical Inc?
What factors affect Biomarin Pharmaceutical Inc?
Which trading strategies trade Biomarin Pharmaceutical Inc?
How are Biomarin Pharmaceutical Inc returns analysed?
Where can I download free Biomarin Pharmaceutical Inc historical data?
Free Biomarin Pharmaceutical Inc historical data (last 10 years)
Browse or instantly download the last 10 years of Biomarin Pharmaceutical Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.BMRN.NASDAQ&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 60.41 |
| 2026-11-19 | 61.42 |
| 2026-11-18 | 61.43 |
| 2026-11-17 | 58.51 |
| 2026-11-16 | 57.99 |
| 2026-11-13 | 57.23 |
| 2026-11-12 | 56.7 |
| 2026-11-11 | 58.33 |
| 2026-11-10 | 57.13 |
| 2026-11-09 | 57.18 |
About this stock
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.